StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Question

<< Previous

Bullboard Posts

Next >>

Comment by LithLoveron Mar 22, 2022 10:42am

91 Views

Post# 34534300

RE:RE:Question

Care added just under $400,000 in revenue in Sept. If they keep up that pace over the 10 months Sept-June they would hit $4 million in June/July and achieve the milestone.

molotov420 wrote: asking people their opinion is alway dangerous here lol. Jogo is gonna tell ya how its an easy quadruple up.

I certainly hope HC revenues dont start to come down for any reason. Remember they have a lot more shares coming their way if they meet some financial goals.
"The milestones are the generation of US$4M in revenue from the AVRT program over any consecutive 12 month period from September 2021 to December 2022."
I expect they will meet this requirement and collect their shares.